Tirzepatide cuts major cardiovascular events 25% vs. GLP-1RAs in type 2 diabetes patients with ASCVD
Background
Patients with Type 2 Diabetes (T2D) face a significantly elevated risk of Atherosclerotic Cardiovascular Disease (ASCVD), which remains a leading cause of morbidity and mortality. While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated cardiovascular benefits, the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, Tirzepatide, offers enhanced glycemic control and weight loss. However, direct comparative evidence on its cardiovascular outcomes against established GLP-1RAs in high-risk T2D patients with ASCVD has been limited, representing a critical gap in guiding treatment decisions.
Study Design
Researchers conducted a retrospective, propensity score-matched cohort study using the TriNetX network to compare cardiovascular outcomes. A total of 16,402 patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease initiating Tirzepatide or GLP-1 receptor agonists between January 1, 2022, and March 31, 2025, were matched 1:1. The primary endpoint was the 1-year risk of major adverse cardiovascular events (MACE). Secondary outcomes included all-cause mortality, acute myocardial infarction (AMI), major adverse limb events (MALE), and tissue plasminogen activator (tPA) use.
Results
Tirzepatide demonstrated a significantly lower risk of major adverse cardiovascular events (MACE) compared to GLP-1 receptor agonists. The primary outcome showed a 25% reduction in MACE, with a hazard ratio (HR) of 0.75 [95% CI, 0.63-0.91]. This benefit extended to several secondary outcomes, highlighting a broad cardiovascular protective effect. All-cause mortality was reduced by 31% (HR, 0.69 [95% CI, 0.53-0.90]), while major adverse limb events (MALE) saw an even greater reduction of 41% (HR, 0.59 [95% CI, 0.39-0.88]). Acute myocardial infarction (AMI) risk was also lowered by 30% (HR, 0.70 [95% CI, 0.53-0.93]). These robust findings were consistent across various subgroups and sensitivity analyses, reinforcing the observed benefits. Tissue plasminogen activator (tPA) use was not significantly different between groups. The dual agonism of Tirzepatide on GIP and GLP-1 receptors appears to confer superior cardiovascular protection in this high-risk population.
Tirzepatide was associated with a 25% lower risk of major adverse cardiovascular events (HR, 0.75 [95% CI, 0.63-0.91]) compared to GLP-1 receptor agonists.
Key Findings
- Tirzepatide lowered 1-year major adverse cardiovascular events (MACE) by 25% (HR, 0.75 [95% CI, 0.63-0.91]) vs. GLP-1RAs.
- All-cause mortality was reduced by 31% with Tirzepatide (HR, 0.69 [95% CI, 0.53-0.90]).
- Major adverse limb events (MALE) decreased by 41% with Tirzepatide (HR, 0.59 [95% CI, 0.39-0.88]).
- Acute myocardial infarction (AMI) risk fell by 30% with Tirzepatide (HR, 0.70 [95% CI, 0.53-0.93]).
Why It Matters
This study provides compelling real-world evidence suggesting Tirzepatide offers superior cardiovascular protection compared to existing GLP-1RAs in patients with Type 2 Diabetes and established ASCVD. For clinicians, this implies that Tirzepatide may be a preferred therapeutic option for this high-risk population, potentially shifting treatment paradigms beyond glycemic control and weight management. For individuals managing T2D and ASCVD, this data supports discussing Tirzepatide with their healthcare providers as a potentially more effective strategy for reducing critical cardiovascular events. The findings underscore the enhanced cardiometabolic potential of dual GIP/GLP-1 receptor agonism, warranting its consideration in comprehensive disease management protocols.
tirzepatide
glp-1ra
type-2-diabetes
cardiovascular-disease
mace
cohort-study